Author Index (Volume 16)

European Neuropsychopharmacology (2006) 16, 625 — 629

www.elsevier.com/locate/euroneuro

Author Index (Volume 16) Abate, M., see Bocchio-Chiavetto, L., 620 Adan, R.A.H., see Hillebrand, J.J.G., 403 Aguilar, E., see Saldan ˜a, M., 491 Ahn, Y.M., see Kim, J.-H., 459 Andersen, E.W., see Stein, D.J., 33 Andreatini, R., see Consoni, F.T., 451 Apter, A., see Tyano, S., 49 Arezzi, A., see Micale, V., 538 Artigas, F., see Dı´az-Mataix, L., 288 Avgustinovich, D.F., see Kudryavtseva, N., 504 Babar, E., see Melik, E., 241 Baker, D., see de Lago, E., 7 Bao, L., see Yu, L., 170 Barak, P., see Barkan, T., 572 Barak, Y., see Friedman, T., 413 Barkan, T., Hermesh, H., Marom, S., Gurwitz, D., Weizman, A. and Rehavi, M., Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals, 19 Barkan, T., Peled, A., Modai, I., Barak, P., Weizman, A. and Rehavi, M., Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients, 572 Barkan, T., Peled, A., Modai, I., Weizman, A. and Rehavi, M., Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals, 429 Basile, V.S., see Levitan, R.D., 1 Becker, J., see Ghisolfi, E.S., 204 Benkelfat, C., see Casey, K.F., 512 Benkelfat, C., see Leyton, M., 220 Bernstein, I., see Carmody, T.J., 601 Bespalov, A.Y., see Kos, T., 297 Blokhina, E., see Kos, T., 297 Blum, I., see Tyano, S., 49 Bocchio-Chiavetto, L., Zanardini, R., Bortolomasi, M., Abate, M., Segala, M., Giacopuzzi, M., Riva, M.A., Marchina, E., Pasqualetti, P., Perez, J. and Gennarelli, M., Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients, 620 Boksa, J., see Daniel, W.A., 580 Bonastre, M., see Saldan ˜a, M., 491 Bortolomasi, M., see Bocchio-Chiavetto, L., 620 Brannan, S., see Carmody, T.J., 601 Breier, A., see Carlson, C., 366 Brenner, S., see Friedman, T., 413 Briyal, S., see Gupta, Y.K., 85 Burnham, D., see Carmody, T.J., 601

Cabranes, A., see de Lago, E., 7 Carboni, L., Vighini, M., Piubelli, C., Castelletti, L., Milli, A. and Domenici, E., Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists, 521 Carlson, C., Hornbuckle, K., DeLisle, F., Kryzhanovskaya, L., Breier, A. and Cavazzoni, P., Diabetes mellitus and antipsychotic treatment in the United Kingdom, 366 Carmody, T.J., Rush, A.J., Bernstein, I., Warden, D., Brannan, S., ¨sberg Burnham, D., Woo, A. and Trivedi, M.H., The Montgomery A and the Hamilton ratings of depression: A comparison of measures, 601 Casey, K.F., Benkelfat, C., Young, S.N. and Leyton, M., Lack of effect of acute dopamine precursor depletion in nicotinedependent smokers, 512 Castelletti, L., see Carboni, L., 521 Cavazzoni, P., see Carlson, C., 366 Celada, P., see Dı´az-Mataix, L., 288 Chai, Y.-G., see Choi, I.-G., 123 Chang, L., see Qu, Y., 561 Chen, T.-J., see Yu, Y.W.-Y., 498 Choi, I.-G., Kee, B.S., Son, H.-G., Ham, B.J., Yang, B.-H., Kim, S.H., Lee, J.-S., Son, B.K., Lee, B.-Y., Lee, S.-Y., Chai, Y.-G. and Shin, H.D., Genetic polymorphisms of alcohol and aldehyde dehydrogenase, dopamine and serotonin transporters in familial and non-familial alcoholism, 123 Cohen, D., Dekker, J.J., Peen, J. and Gispen-de Wied, C.C., Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment, 187 Connor, T.J., see Diamond, M., 481 Consensus Committee, see Van den Brink, W., 224 Consoni, F.T., Vital, M.A.B.F. and Andreatini, R., Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test, 451 Cools, A.R., see de Jong, T.R., 39 Croke, D.T., see Tomiyama, K., 437 Cumming, P., see Smith, D.F., 350 Daniel, W.A., Haduch, A., Syrek, M. and Boksa, J., Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment, 580 Daniel, W.A., see Haduch, A., 178 Danysz, W., see Kos, T., 297 De Bartolomeis, A., see De Luca, V., 268 De Deyn, P.P., see Van Dam, D., 59 De Haan, L., see van Beveren, N.J.M., 469 De Jong, C.A.J., see Roozen, H.G., 311

0924-977X/$ - see front matter n 2006 Elsevier B.V. and ECNP. All rights reserved. doi:10.1016/S0924-977X(06)00211-2

626 De Jong, T.R., Snaphaan, L.J.A.E., Pattij, T., Veening, J.G., Waldinger, M.D., Cools, A.R. and Olivier, B., Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats, 39 De Lago, E., Ferna ´ndez-Ruiz, J., Ortega-Gutie ´rrez, S., Cabranes, A., Pryce, G., Baker, D., Lo ´pez-Rodrı´guez, M. and Ramos, J.A., UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders, 7 De Luca, V., Zai, G., Tharmalingam, S., de Bartolomeis, A., Wong, G. and Kennedy, J.L., Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia, 268 De Waart, R., see Roozen, H.G., 311 Deforce, D., see Denys, D., 446 Dekker, J.J., see Cohen, D., 187 DeLisle, F., see Carlson, C., 366 Deluca, V., see Hwang, R., 248 Denys, D., Van Nieuwerburgh, F., Deforce, D. and Westenberg, H., Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive—compulsive disorder in males, 446 Deutsch, L.H., see Deutsch, S.I., 547 Deutsch, S.I., Rosse, R.B. and Deutsch, L.H., Faulty regulation of tau phosphorylation by the reelin signal transduction pathway is a potential mechanism of pathogenesis and therapeutic target in Alzheimer’s disease, 547 Diamond, M., Kelly, J.P. and Connor, T.J., Antidepressants suppress production of the Th1 cytokine interferon-g, independent of monoamine transporter blockade, 481 Dı´az-Mataix, L., Artigas, F. and Celada, P., Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist, 288 Diksic, M., see Leyton, M., 220 Domenici, E., see Carboni, L., 521 Doron, R., see Maayan, R., 329 Drago, F., see Micale, V., 195 Drago, F., see Micale, V., 538 Dravolina, O., see Kos, T., 297 Eidi, A., Eidi, M., Mahmoodi, G. and Oryan, S., Effect of vitamin E on memory retention in rats: Possible involvement of cholinergic system, 101 Eidi, M., see Eidi, A., 101 Elferink, A.J.A., see Wohlfarth, T.D., 79 Emsley, R., see Kennedy, S.H., 93 Fang, J., see Yu, L., 170 Farzin, D. and Mansouri, N., Antidepressant-like effect of harmane and other h-carbolines in the mouse forced swim test, 324 Fekkes, D., see Hoekstra, R., 71 Fekkes, D., see van Beveren, N.J.M., 469 Ferna ´ndez-Ruiz, J., see de Lago, E., 7 Fienberg, A.A., see Tomiyama, K., 437 Fredholm, B.B., see Kuzmin, A., 129 Friedman, T., Wohl, Y., Knobler, H.Y., Lubin, G., Brenner, S., Levi, Y. and Barak, Y., Increased use of mental health services related to Isotretinoin treatment: A 5-year analysis, 413 Fudge, M.A., Kavaliers, M. and Ossenkopp, K.-P., Allopregnanolone produces hyperphagia by reducing neophobia without altering food palatability, 272 Galankin, T., see Kos, T., 297 Gartside, S.E., see Judge, S.J., 612 Gennarelli, M., see Bocchio-Chiavetto, L., 620

Author Index (Volume 16) Gerrits, M.A.F.M., Wolterink, G. and van Ree, J.M., Cerebral metabolic consequences in the adult brain after neonatal excitotoxic lesions of the amygdala in rats, 358 Gerrits, M.A.F.M., see Kudryavtseva, N., 504 Ghisolfi, E.S., Schuch, A., Strimitzer Jr., I.M., Luersen, G., Martins, F.F., Ramos, F.L.P., Becker, J. and Lara, D.R., Caffeine modulates P50 auditory sensory gating in healthy subjects, 204 Giacopuzzi, M., see Bocchio-Chiavetto, L., 620 Gibel, A., see Ritsner, M., 137 Gilani, R.A., see Nadeem, A., 260 Gimenez, L., see Kuzmin, A., 129 Gispan-Herman, I., see Maayan, R., 329 Gispen-de Wied, C.C., see Cohen, D., 187 Gispen-de Wied, C.C., see Wohlfarth, T.D., 79 Grandy, D.K., see Tomiyama, K., 437 Gravel, P., see Leyton, M., 220 Green, P., Hermesh, H., Monselise, A., Marom, S., Presburger, G. and Weizman, A., Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder, 107 Greenstein, D., see Qu, Y., 561 Gruber, S.H.M., Nomikos, G.G. and Mathe ´, A.A., Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs, 592 Gru ¨nder, G., see Medori, R., 233 Gupta, Y.K. and Briyal, S., Protective effect of vineatrol against kainic acid induced seizures, oxidative stress and on the expression of heat shock proteins in rats, 85 Gurwitz, D., see Barkan, T., 19 Haduch, A., Wo ´jcikowski, J. and Daniel, W.A., The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A, 178 Haduch, A., see Daniel, W.A., 580 Halonen, P., see Tupala, E., 552 Ham, B.J., see Choi, I.-G., 123 Hamon, M., see Loiseau, F., 417 Hanoch-Levi, A., see Nevo, G.A., 588 Hansen, S.B., see Smith, D.F., 350 Hara, C., see Nishitsuji, K., 376 Harell, D., see Tyano, S., 49 Hermesh, H., see Barkan, T., 19 Hermesh, H., see Green, P., 107 Hershko, R., see Nevo, G.A., 588 Hess, G., see Zahorodna, A., 383 Higuchi, S., see Nishitsuji, K., 376 Hillebrand, J.J.G., Kas, M.J.H., Scheurink, A.J.W., van Dijk, G. and Adan, R.A.H., AgRP(83—132) and SHU9119 differently affect activity-based anorexia, 403 Hoekstra, R., Fekkes, D., Loonen, A.J.M., Pepplinkhuizen, L., Tuinier, S. and Verhoeven, W.M.A., Bipolar mania and plasma amino acids: Increased levels of glycine, 71 Hong, C.-J., see Yu, Y.W.-Y., 498 Hornbuckle, K., see Carlson, C., 366 Hwang, R., Shinkai, T., Deluca, V., Macciardi, F., Potkin, S., Meltzer, H.Y. and Kennedy, J.L., Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment, 248 Ignoto, A., see Micale, V., 195 Incognito, T., see Micale, V., 195 Jakobsen, S., see Smith, D.F., 350 Johansson, B., see Kuzmin, A., 129

Author Index (Volume 16) Judge, S.J., Young, R.L. and Gartside, S.E., GABA A receptor modulation of 5-HT neuronal firing in the median raphe nucleus: Implications for the action of anxiolytics, 612 Kaplan, A.S., see Levitan, R.D., 1 Kas, M.J.H., see Hillebrand, J.J.G., 403 Kavaliers, M., see Fudge, M.A., 272 Kee, B.S., see Choi, I.-G., 123 Kelly, J.P., see Diamond, M., 481 Kennedy, J.L., see De Luca, V., 268 Kennedy, J.L., see Hwang, R., 248 Kennedy, J.L., see Levitan, R.D., 1 Kennedy, S.H. and Emsley, R., Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, 93 Kerkhof, Ad.J.F.M., see Roozen, H.G., 311 Kim, J.-H., Yi, S.H., Park, K.T., Ahn, Y.M., Lee, K.Y., Yang, S.A. and Kim, Y.S., Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome, 459 Kim, S.H., see Choi, I.-G., 123 Kim, Y.S., see Kim, J.-H., 459 Kinsella, A., see Tomiyama, K., 437 Klaff, J., see Qu, Y., 561 Knobler, H.Y., see Friedman, T., 413 Kos, T., Popik, P., Pietraszek, M., Scha ¨fer, D., Danysz, W., Dravolina, O., Blokhina, E., Galankin, T. and Bespalov, A.Y., Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice, 297 Koshikawa, N., see Tomiyama, K., 437 Kryzhanovskaya, L., see Carlson, C., 366 Kudryavtseva, N., Gerrits, M.A.F.M., Avgustinovich, D.F., Tenditnik, M.V. and Van Ree, J.M., Anxiety and ethanol consumption in victorious and defeated mice; effect of n-opioid receptor activation, 504 ¨ gren, S.-O. and Fredholm, Kuzmin, A., Johansson, B., Gimenez, L., O B.B., Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice, 129 Lader, M., see Stein, D.J., 33 Lara, D.R., see Ghisolfi, E.S., 204 Le Bihan, C., see Loiseau, F., 417 Lee, B.-Y., see Choi, I.-G., 123 Lee, J.-S., see Choi, I.-G., 123 Lee, K.Y., see Kim, J.-H., 459 Lee, S.-Y., see Choi, I.-G., 123 Lekkerkerker, F.J., see Wohlfarth, T.D., 79 Lerer, B., see Lifschytz, T., 115 Levi, Y., see Friedman, T., 413 Levitan, R.D., Kaplan, A.S., Masellis, M., Basile, V.S., Richter, M.A. and Kennedy, J.L., The serotonin-1Dh receptor gene and severity of obsessive-compulsive disorder in women with bulimia nervosa, 1 Leyton, M., Paquette, V., Gravel, P., Rosa-Neto, P., Weston, F., Diksic, M. and Benkelfat, C., a-[11C]Methyl-l-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters, 220 Leyton, M., see Casey, K.F., 512 Lifschytz, T., Shalom, G., Lerer, B. and Newman, M.E., Sexdependent effects of fluoxetine and triiodothyronine in the forced swim test in rats, 115 Lin, H.-C., see Wan, F.-J., 147 Liou, Y.-J., see Yu, Y.W.-Y., 498 Loiseau, F., Le Bihan, C., Hamon, M. and Thie ´bot, M.-H., Effects of melatonin and agomelatine in anxiety-related procedures in rats: Interaction with diazepam, 417 Loonen, A.J.M., see Hoekstra, R., 71 Lo ´pez-Rodrı´guez, M., see de Lago, E., 7 Lotan, S., see Maayan, R., 329

627 Lubin, G., see Friedman, T., 413 Luersen, G., see Ghisolfi, E.S., 204 Ma, R., see Yu, L., 170 Maayan, R., Lotan, S., Doron, R., Shabat-Simon, M., Gispan-Herman, I., Weizman, A. and Yadid, G., Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats, 329 Maayan, R., see Ritsner, M., 137 Maayan, R., see Strous, R.D., 155 Macciardi, F., see Hwang, R., 248 Mahmoodi, G., see Eidi, A., 101 Makihara, Y., see Tomiyama, K., 437 Mannaert, E., see Medori, R., 233 Mansouri, N., see Farzin, D., 324 Marchina, E., see Bocchio-Chiavetto, L., 620 Marin, C., see Saldan ˜a, M., 491 Marom, S., see Barkan, T., 19 Marom, S., see Green, P., 107 Martenyi, F. and Soldatenkova, V., Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebocontrolled, randomized clinical trial, 340 Marthi, K., see Smith, D.F., 350 Martins, F.F., see Ghisolfi, E.S., 204 Masellis, M., see Levitan, R.D., 1 Masood, A., see Nadeem, A., 260 Masood, N., see Nadeem, A., 260 Mathe ´, A.A., see Gruber, S.H.M., 592 Mayan, R., see Roth-Deri, I., 25 Medori, R., Mannaert, E. and Gru ¨nder, G., Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable, 233 Meged, S., see Nevo, G.A., 588 Melik, E., Babar, E., Ozen, E. and Ozgunen, T., Hypofunction of the dorsal hippocampal NMDA receptors impairs retrieval of memory to partially presented foreground context in a single-trial fear conditioning in rats, 241 Meltzer, H.Y., see Hwang, R., 248 Micale, V., Arezzi, A., Rampello, L. and Drago, F., Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission, 538 Micale, V., Incognito, T., Ignoto, A., Rampello, L., Sparta `, M. and Drago, F., Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury, 195 Milli, A., see Carboni, L., 521 Mine, K., see Nishitsuji, K., 376 Modai, I., see Barkan, T., 429 Modai, I., see Barkan, T., 572 Monselise, A., see Green, P., 107 Montgomery, S.A., see Van den Brink, W., 224 Munk, O.L., see Smith, D.F., 350 Nadeem, A., Masood, A., Masood, N., Gilani, R.A. and Shah, Z.A., Immobilization stress causes extra-cellular oxidant—antioxidant imbalance in rats: Restoration by L-NAME and vitamin E, 260 Nally, R.E., see Tomiyama, K., 437 Nevo, G.A., Meged, S., Sela, B.A., Hanoch-Levi, A., Hershko, R. and Weizman, A., Homocysteine levels in adolescent schizophrenia patients, 588 Newman, M.E., see Lifschytz, T., 115 Nishitsuji, K., To, H., Shimizu, T., Yanase, Y., Yamada, T., Hara, C., Mine, K. and Higuchi, S., The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress, 376 Nomikos, G.G., see Gruber, S.H.M., 592

628 Ofek, H., see Tyano, S., 49 ¨ gren, S.-O., see Kuzmin, A., 129 O Olivier, B., see de Jong, T.R., 39 Ortega-Gutie ´rrez, S., see de Lago, E., 7 Oryan, S., see Eidi, A., 101 Ossenkopp, K.-P., see Fudge, M.A., 272 O’Sullivan, G., see Tomiyama, K., 437 Ozen, E., see Melik, E., 241 Ozgunen, T., see Melik, E., 241 Papakostas, G.I., Dopaminergic-based pharmacotherapies for depression, 391 Paquette, V., see Leyton, M., 220 Park, K.T., see Kim, J.-H., 459 Pasqualetti, P., see Bocchio-Chiavetto, L., 620 Pattij, T., see de Jong, T.R., 39 Peen, J., see Cohen, D., 187 Peled, A., see Barkan, T., 429 Peled, A., see Barkan, T., 572 Pepplinkhuizen, L., see Hoekstra, R., 71 Perez, J., see Bocchio-Chiavetto, L., 620 Pick, C.G., see Schreiber, S., 464 Pietraszek, M., see Kos, T., 297 Piubelli, C., see Carboni, L., 521 Popik, P., see Kos, T., 297 Potkin, S., see Hwang, R., 248 Presburger, G., see Green, P., 107 Pryce, G., see de Lago, E., 7 Qu, Y., Chang, L., Klaff, J., Seemann, R., Greenstein, D. and Rapoport, S.I., Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats, 561 Ram, E., see Ritsner, M., 137 Ramos, F.L.P., see Ghisolfi, E.S., 204 Ramos, J.A., see de Lago, E., 7 Rampello, L., see Micale, V., 195 Rampello, L., see Micale, V., 538 Rapoport, S.I., see Qu, Y., 561 Rehavi, M., see Barkan, T., 19 Rehavi, M., see Barkan, T., 429 Rehavi, M., see Barkan, T., 572 Richter, M.A., see Levitan, R.D., 1 Ritsner, M., Gibel, A., Ram, E., Maayan, R. and Weizman, A., Alterations in DHEA metabolism in schizophrenia: Two-month case-control study, 137 Riva, M.A., see Bocchio-Chiavetto, L., 620 Roozen, H.G., de Waart, R., van der Windt, D.A.W.M., van den Brink, W., de Jong, C.A.J. and Kerkhof, Ad.J.F.M., A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence, 311 Rosa-Neto, P., see Leyton, M., 220 Rosse, R.B., see Deutsch, S.I., 547 Roth-Deri, I., Mayan, R. and Yadid, G., A hypothalamic endorphinic lesion attenuates acquisition of cocaine self-administration in the rat, 25 Ruis, J.R., see Wohlfarth, T.D., 79 Rush, A.J., see Carmody, T.J., 601 Saldan ˜a, M., Bonastre, M., Aguilar, E. and Marin, C., Role of nigral NFnB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats, 491 Scha ¨fer, D., see Kos, T., 297 Scheurink, A.J.W., see Hillebrand, J.J.G., 403 Schreiber, S. and Pick, C.G., From selective to highly selective SSRIs: A comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram, 464

Author Index (Volume 16) Schuch, A., see Ghisolfi, E.S., 204 Seemann, R., see Qu, Y., 561 Segala, M., see Bocchio-Chiavetto, L., 620 Sela, B.A., see Nevo, G.A., 588 Shabat-Simon, M., see Maayan, R., 329 Shah, Z.A., see Nadeem, A., 260 Shalom, G., see Lifschytz, T., 115 Sher, L., see Tyano, S., 49 Shiah, I.-S., see Wan, F.-J., 147 Shimizu, T., see Nishitsuji, K., 376 Shin, H.D., see Choi, I.-G., 123 Shinkai, T., see Hwang, R., 248 Sibley, D.R., see Tomiyama, K., 437 Smeraldi, E., see Zanardi, R., 281 Smith, D.F., Marthi, K., Munk, O.L., Cumming, P., Hansen, S.B. and Jakobsen, S., PET neuroimaging of [11C]mirtazapine enantiomers in pigs, 350 Snaphaan, L.J.A.E., see de Jong, T.R., 39 Soldatenkova, V., see Martenyi, F., 340 Sommerfeld, E., see Tyano, S., 49 Son, B.K., see Choi, I.-G., 123 Son, H.-G., see Choi, I.-G., 123 Sparta `, M., see Micale, V., 195 Stein, D.J., Andersen, E.W. and Lader, M., Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions, 33 Storosum, J.G., see Wohlfarth, T.D., 79 Storvik, M., Tiikkainen, P., van Iersel, M. and Wong, G., Distinct gene expression profiles in adult rat brains after acute MK-801 and cocaine treatments, 211 Strimitzer Jr., I.M., see Ghisolfi, E.S., 204 Strous, R.D., Maayan, R. and Weizman, A., The relevance of neurosteroids to clinical psychiatry: From the laboratory to the bedside, 155 Syrek, M., see Daniel, W.A., 580 Tenditnik, M.V., see Kudryavtseva, N., 504 Tharmalingam, S., see De Luca, V., 268 Thie ´bot, M.-H., see Loiseau, F., 417 Tighe, O., see Tomiyama, K., 437 Tiihonen, J., see Tupala, E., 552 Tiikkainen, P., see Storvik, M., 211 To, H., see Nishitsuji, K., 376 Tokarski, K., see Zahorodna, A., 383 Tomiyama, K., Makihara, Y., Yamamoto, H., O’Sullivan, G., Nally, R.E., Tighe, O., Kinsella, A., Fienberg, A.A., Grandy, D.K., Sibley, D.R., Croke, D.T., Koshikawa, N. and Waddington, J.L., Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction dknockoutT, 437 Trivedi, M.H., see Carmody, T.J., 601 Tsai, S.-J., see Yu, Y.W.-Y., 498 Tuinier, S., see Hoekstra, R., 71 Tung, C.-S., see Wan, F.-J., 147 Tupala, E., Halonen, P. and Tiihonen, J., Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography, 552 Tyano, S., Zalsman, G., Ofek, H., Blum, I., Apter, A., Wolovik, L., Sher, L., Sommerfeld, E., Harell, D. and Weizman, A., Plasma serotonin levels and suicidal behavior in adolescents, 49 Van Beveren, N.J.M., van der Spelt, J.-J., de Haan, L. and Fekkes, D., Schizophrenia-associated neural growth factors in peripheral blood. A review, 469 Van Dam, D. and De Deyn, P.P., Cognitive evaluation of diseasemodifying efficacy of Galantamine and Memantine in the APP23 model, 59

Author Index (Volume 16) Van den Brink, W., Montgomery, S.A., Van Ree, J.M., van ZwietenBoot, B.J. and on behalf of the Consensus Committee, ECNP consensus meeting March 2003 guidelines for the investigation of efficacy in substance use disorders, 224 Van den Brink, W., see Roozen, H.G., 311 Van der Spelt, J.-J., see van Beveren, N.J.M., 469 Van der Windt, D.A.W.M., see Roozen, H.G., 311 Van Dijk, G., see Hillebrand, J.J.G., 403 Van Iersel, M., see Storvik, M., 211 Van Nieuwerburgh, F., see Denys, D., 446 Van Ree, J.M., see Kudryavtseva, N., 504 Van Ree, J.M., see Van den Brink, W., 224 Van Ree, J.M., see Gerrits, M.A.F.M., 358 Van Zwieten, B.J., see Wohlfarth, T.D., 79 Van Zwieten-Boot, B.J., see Van den Brink, W., 224 Veening, J.G., see de Jong, T.R., 39 Verhoeven, W.M.A., see Hoekstra, R., 71 Vighini, M., see Carboni, L., 521 Vital, M.A.B.F., see Consoni, F.T., 451 Waddington, J.L., see Tomiyama, K., 437 Waldinger, M.D., see de Jong, T.R., 39 Wan, F.-J., Tung, C.-S., Shiah, I.-S. and Lin, H.-C., Effects of aphenyl-N-tert-butyl nitrone and N-acetylcysteine on hydroxyl radical formation and dopamine depletion in the rat striatum produced by d-amphetamine, 147 Warden, D., see Carmody, T.J., 601 Weizman, A., see Barkan, T., 19 Weizman, A., see Barkan, T., 429 Weizman, A., see Barkan, T., 572 Weizman, A., see Green, P., 107 Weizman, A., see Maayan, R., 329 Weizman, A., see Nevo, G.A., 588 Weizman, A., see Ritsner, M., 137 Weizman, A., see Strous, R.D., 155 Weizman, A., see Tyano, S., 49 Westenberg, H., see Denys, D., 446 Weston, F., see Leyton, M., 220 Wohl, Y., see Friedman, T., 413 Wohlfarth, T.D., van Zwieten, B.J., Lekkerkerker, F.J., Gispen-de Wied, C.C., Ruis, J.R., Elferink, A.J.A. and Storosum, J.G., Antidepressants use in children and adolescents and the risk of suicide, 79

629 Wo ´jcikowski, J., see Haduch, A., 178 Wolovik, L., see Tyano, S., 49 Wolterink, G., see Gerrits, M.A.F.M., 358 Wong, G., see De Luca, V., 268 Wong, G., see Storvik, M., 211 Woo, A., see Carmody, T.J., 601 Yadid, G., see Maayan, R., 329 Yadid, G., see Roth-Deri, I., 25 Yamada, T., see Nishitsuji, K., 376 Yamamoto, H., see Tomiyama, K., 437 Yanase, Y., see Nishitsuji, K., 376 Yang, B.-H., see Choi, I.-G., 123 Yang, S.A., see Kim, J.-H., 459 Yi, S.H., see Kim, J.-H., 459 Young, R.L., see Judge, S.J., 612 Young, S.N., see Casey, K.F., 512 Yu, L., Zhang, Y., Ma, R., Bao, L., Fang, J. and Yu, T., Potent protection of ferulic acid against excitotoxic effects of maternal intragastric administration of monosodium glutamate at a late stage of pregnancy on developing mouse fetal brain, 170 Yu, T., see Yu, L., 170 Yu, Y.W.-Y., Tsai, S.-J., Liou, Y.-J., Hong, C.-J. and Chen, T.-J., Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders, 498 Zahorodna, A., Tokarski, K. and Hess, G., Imipramine treatment ameliorates corticosterone-induced alterations in the effects of 5-HT1A and 5-HT4 receptor activation in the CA1 area of rat hippocampus, 383 Zai, G., see De Luca, V., 268 Zalsman, G., see Tyano, S., 49 Zanardi, R. and Smeraldi, E., A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia, 281 Zanardini, R., see Bocchio-Chiavetto, L., 620 Zhang, Y., see Yu, L., 170